Systematic Reviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 27, 2023; 15(8): 1001-1012
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.1001
Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
Jasmine Tidwell, Natalie Balassiano, Anjiya Shaikh, Mahmoud Nassar
Jasmine Tidwell, Anjiya Shaikh, Department of Internal Medicine, University of Connecticut, Farmington, CT 06032, United States
Natalie Balassiano, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals/Queens, New York, NY 11432, United States
Mahmoud Nassar, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY 14221, United States
Author contributions: Tidwell J and Balassiano N performed the screening of articles, extraction of data and wrote the manuscript; Tidwell J and Shaikh A contributed to the results and discussion section; Nassar M contributed to editing, formatting and reviewing; All authors have read and approve the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mahmoud Nassar, MD, MSc, PhD, Doctor, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, WNY 705 Maple Road, Williamsville, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Received: April 30, 2023
Peer-review started: April 30, 2023
First decision: June 7, 2023
Revised: June 18, 2023
Accepted: August 7, 2023
Article in press: August 7, 2023
Published online: August 27, 2023
Core Tip

Core Tip: Non-alcoholic fatty liver disease (NAFLD) has become a significant global health issue. There is no medication approved by the Federal Drug Administration for the treatment of NAFLD. However, there are several therapeutic classes currently being studied in clinical trials. In this systematic review, we analyze the scientific data of cyclophilin inhibitors, fibroblast growth factor 21 analogs, and dual and pan peroxisome proliferator-activated receptor agonists for the treatment of NAFLD.